

Attendance:

Dean Jolley (Jolley's Compounding Pharmacy)

Rob Smith (Rock Canyon Pharmacy)

Jacob Corsi (Isomeric)

Kyle Kitchen (Intermountain Outpatient Clinics)

Greg Myers (Intermountain Health Care)

Karin Caestia (Alpine Apothecary)

Christine Jacobsen (Wasatch Pharmacy)

Chris Cox (Smith Rexall Drug)

Donelle Perez (Petersen's)

Jessica Patton (UOU Intern-4th Year)

Travis Drebing (DOPL)

Sharilee McIntyre (DOPL)

Trip Hoffman (University Pharmacy-Chair of Task Force)

For Office Discussion and Update:

The Board and DOPL were ready to adopt our rules that we worked on and supported the practice of FOU compounded products but road blocks and barricades kept popping up every time DOPL went to get complete clarification. What was said each time was that the federal law did not allow FOU compounding (sterile or non-sterile) and that a compound must be for an identified individual patient and dispensed without would be in violation by being deemed adulterated and misbranded.

So we need a plan to help fix the problems with the DQSA: Griffith and Alexander within the House and Senate are currently working on new bills to correct the FOU issue. There seems to be a bigger approach to involve prescribing practitioners more in the fight as well.

Plan is to write a letter to our State leaders so they know where stakeholders in Utah stand and why it is so important to get FOU back in our State. Gap in providing non-sterile FOU products (503b or Outsourcing Facilities under the FDA) simply are not providing all products. Also, we as a task force and as individuals need to get on board with David Miller and IACP with the "fix the DQSA" campaign. It is a goal of the task force to get communication out to all compounding pharmacies better but we do encourage pharmacies to look at the DOPL website.

Greg Myers pointed out that the LET gels and creams are a major issue for some critical care sites and their patients. Not being able to provide non-sterile FOU medications affects cost as well as the care for our patients and hopefully we will see FOU under state jurisdiction once again in 2015.

Tips to help pass a DOPL inspection:

Several members have had recent inspections and we thought it would be great to share what the inspectors are finding over and over at most pharmacies. In general, we are seeing more letters of concern and more education from DOPL, but we should learn from the repeated violations among numerous pharmacies to educate our staff and make this an opportunity for growth and improving our pharmacies.

See attached document for a list of the major violations

Providing Prescription Blanks:

What is allowed and does DOPL have an issue? It seems that there are questions and concerns regarding this type of practice. There needs to be more discussion in this area for what is allowed and what is not allowed. It is best practice not to include your pharmacy name on any template for a prescription blank. It is also important that if prescription blanks contain controlled substances, then check boxes should not be used. More discussion needed.

Pain Cream Update:

This practice is dying down and seems to be getting under control. Dean Jolley talked about several insurance companies are considering new models for reimbursement such as looking at a level of effort in more detail.

Sample labeling information:

Sample labeling information required not a sample label is now in rule under R156-17b-614a (3) d iv. Sample labeling information must include: generic name and quantity or concentration of each active ingredient, assigned BUD, storage conditions, and rx or control number.